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Objectives We investigated whether reduced cardiovascular risk is more related to the progressive decrease of asleep or
awake blood pressure.
Background Independent studies have concluded that elevated sleep-time blood pressure is a better predictor of cardiovascu-
lar risk than awake or 24-h blood pressure means. However, the impact on cardiovascular risk of changes in
these ambulatory blood pressure characteristics has not been properly investigated.
Methods We prospectively studied 3,344 subjects (1,718 men and 1,626 women), 52.6  14.5 years of age, during a
median follow-up of 5.6 years. Those with hypertension at baseline were randomized to ingest all their pre-
scribed hypertension medications upon awakening or 1 of them at bedtime. Blood pressure was measured for
48 h at baseline and again annually or more frequently (quarterly) if treatment adjustment was required.
Results With data collected at baseline, when asleep blood pressure was adjusted by awake mean, only the former was
a significant predictor of outcome in a Cox proportional hazards model also adjusted for sex, age, and diabetes.
Analyses of changes in ambulatory blood pressure during follow-up revealed a 17% reduction in cardiovascular
risk for each 5-mm Hg decrease in asleep systolic blood pressure mean (p  0.001), independently of changes
in any other ambulatory blood pressure parameter.
Conclusions The sleep-time blood pressure mean is the most significant prognostic marker of cardiovascular morbidity and
mortality. Most importantly, the progressive decrease in asleep blood pressure, a novel therapeutic target that
requires proper patient evaluation by ambulatory monitoring, was the most significant predictor of event-free
survival. (Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events
and Effects of Chronotherapy in Relation to Risk [the MAPEC Study]; NCT00295542) (J Am Coll Cardiol 2011;
58:1165–73) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.043During the past 2 decades, specific features of the 24-h
blood pressure (BP) pattern determined by ambulatory
blood pressure monitoring (ABPM) have been assessed as
potential sources of injury to target tissues and triggers of
cardiac and cerebrovascular events. For instance, the extent
of the BP surge upon wakening has been associated with
increased cardiovascular disease (CVD) morbidity and mor-
tality in some but not all studies (1,2). A growing number of
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2011, accepted April 21, 2011.studies (3–6) have consistently shown an association between
blunted asleep BP decline and increased incidence of fatal and
nonfatal CVD events. Independent prospective studies have
also concluded that the asleep BP mean is a better predictor of
CVD risk than the awake or 24-h BP means (5–10).
See page 1174
A limitation of all the previous studies on the prognostic
value of ABPM is their reliance on a single baseline profile
from each participant at the time of inclusion, without ac-
counting for possible changes in the level and pattern of
ambulatory BP during the years of follow-up, mainly associ-
ated with hypertension therapy, aging, and developing target
organ damage and/or concomitant diseases. Thus, the poten-
tial reduction in CVD risk associated with modifying prog-
nostic ABPM parameters (i.e., specifically reducing asleep BP)
(9) is still a matter of debate. The MAPEC (Monitorizacio´nmbulatoria para Prediccio´n de Eventos Cardiovasculares [i.e.,
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itoring for Prediction of Cardio-
vascular Events]) study was specif-
ically designed to investigate
prospectively whether specific
changes in the circadian BP profile
results in reduced CVD risk (11).
In particular, we investigated
whether changes of ambulatory BP
characteristics during follow-up
might be related to increased sur-
vival in subjects who were system-
atically evaluated by periodic—at
least annually—ABPM.
Methods
Inclusion and exclusion criteria. An extended version of
Methods is available in the Online Appendix. In summary,
the sample represents a population of Spanish subjects of
both sexes 18 years of age. Inclusion criteria required
subjects to be normotensive, untreated hypertensive, or
resistant to treatment (uncontrolled BP according to the
ABPM threshold values outlined in the following text while
compliant to 3 optimally dosed hypertension medications of
different classes, including a diuretic unless contraindicated
or intolerant or any subject treated with 3 hypertension
medications [12]). Exclusion criteria were pregnancy, his-
tory of drug/alcohol abuse, night/shift-work employment,
diagnosis of acquired immunodeficiency syndrome, type 1
diabetes, secondary hypertension, CVD disorders (unstable
angina pectoris, heart failure, life-threatening arrhythmia,
kidney failure, and grade III to IV retinopathy), intolerance
to ABPM, and inability to communicate and comply with
all of the study requirements. Participants represent a
consecutive series of persons fulfilling these exclusion/
inclusion criteria, recruited among those referred to the
hospital for ABPM evaluation, mainly to confirm/discard
the diagnosis of hypertension suspected by daytime clinic
cuff BP measurement in untreated subjects, or to evaluate
BP control in already treated patients. Additional reasons to
request ABPM included, among several others, impaired
fasting glucose, metabolic syndrome, diabetes, chronic kid-
ney disease, previous complications in pregnancy, suspicion
of sleep disorders, and age over 60 years. This prospective
single-center study (registered online with identifier code
NCT00295542) was approved by the state Ethics Commit-
tee of Clinical Research. All participants gave written
informed consent.
Subjects and diagnostic criteria. Between 2000 and 2007,
we recruited 3,612 subjects fulfilling the inclusion/exclusion
criteria. Among these, 3,344 (1,718 men/1,626 women, age
52.6  14.5 years) provided all required information for the
study. The remaining 268 subjects were eliminated due to
inadequate ABPM sampling at baseline and their lack of
Abbreviations
and Acronyms
ABPM  ambulatory blood
pressure monitoring
BP  blood pressure
CI  confidence interval
CVD  cardiovascular
disease
DBP  diastolic blood
pressure
HR  hazard ratio
SBP  systolic blood
pressureconsent for additional ABPM evaluations. We established apriori a minimum time of follow-up of 6 months for each
subject and a minimum median follow-up of 5 years (11).
Diagnosis of hypertension (in untreated subjects) was based
on accepted ABPM criteria—an awake BP mean of
135/85 mm Hg for systolic blood pressure (SBP)/diastolic
blood pressure (DBP) and/or an asleep BP mean 120/70
mm Hg (13). At the time of recruitment, 734 subjects were
normotensive and 2,610 were hypertensive (776 with resis-
tant hypertension) according to these ABPM criteria.
Study design. Patients with untreated hypertension were
randomly assigned to 1 of 2 monotherapy treatment-time
groups, either upon awakening in the morning or at bedtime
at night, as extensively described elsewhere (14). Random-
ization of subjects to treatment-time (awakening or bed-
time) was done separately for each allowed individual
hypertension medication (valsartan, telmisartan, olmesar-
tan, ramipril, spirapril, amlodipine, nifedipine GITS,
nebivolol, torasemide). This ensured that the proportion of
subjects treated with each medication was similar across the
2 treatment times. If subjects were uncontrolled based on
ABPM criteria after 3 months of monotherapy, additional
medications could be added in keeping with current clinical
practice.
Participants with resistant hypertension were randomized
to either: 1) modify the nature of their treatment, exchang-
ing 1 of their medications with a new 1, thus without
modifying the total number of medications but retaining the
upon-waking ingestion time for all medications; or 2) shift
the ingestion-time of 1 BP-lowering medication to bedtime
(14). After this first randomization, investigators were
allowed to exchange additional medications for others of
different classes (keeping always the upon-waking ingestion
time of all medications) in the first randomized group;
progressively shift additional medications to bedtime in the
second randomized group; or prescribe additional medica-
tions in either group. Changes in therapeutic scheme during
follow-up in uncontrolled subjects (those with ambulatory
BP above the thresholds provided in the preceding text)
were always based on the results from periodic evaluation by
ABPM (see the following text). The protocol did not allow
dividing any prescribed medication in 2 or more doses.
Thus, patients randomized to the bedtime-treatment group
were never ingesting in the morning any of the medications
ingested at bedtime.
Blood samples were obtained the same week each 48-h
ABPM session was initiated. Participants reported to the
hospital between 8:00 AM and 9:00 AM, after overnight
fasting, for blood withdrawal from an antecubital vein.
Samples were analyzed with routine automatic techniques in
the hospital laboratory. Just before commencing ABPM, 6
clinic BP measurements were always obtained by the same
investigator with a validated automatic oscillometric device
(HEM-705IT, Omron Health Care, Inc., Vernon Hills,
Illinois) after the subject had rested in a seated position for
10 min.
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led visit for ABPM during follow-up (see the following
ext), the SBP and DBP of each subject were automatically
easured every 20 min between 7:00 AM and 11:00 PM and
every 30 min during the night for 48 consecutive hours with
a calibrated SpaceLabs 90207 ABPM monitor (SpaceLabs
Inc., Issaquah, Washington). Participants were instructed
to do their usual activities with minimal restrictions but
to adhere to a similar schedule during the 2 days of
ABPM and avoid daytime napping. During monitoring,
subjects maintained a diary listing the times of retiring to
bed at night and awakening in the morning. The BP
series were considered invalid for analysis if 30% of the
measurements were missing, if data were lacking for an
interval of 2 h, or if the nighttime sleep period was 6
or 12 h during ABPM.
Actigraphy. All subjects wore an actigraph (Mini-Motion-
Logger, Ambulatory Monitoring, Inc., Ardsley, New York)
on the dominant wrist to monitor physical activity every min
during 48-h ABPM. The actigraphy data, combined with
patient diaries, were used to corroborate the absence of
daytime napping and define the commencement and termi-
nation of the daytime awake and nocturnal asleep spans so
the respective BP means for each subject could be accurately
determined.
Follow-up. The same evaluation procedure described in
the preceding text—including conventional clinic BP mea-
surement, 48-h ABPM and wrist activity monitoring, and
blood sampling—was scheduled annually in all participants
or more frequently (after 3 months of any change in therapy
in treated subjects) if the therapeutic scheme was modified
to improve ambulatory BP control. Investigators blinded to
the timed-treatment scheme of each participant (thus ex-
cluding those performing clinic evaluation at each visit to
the hospital, clinic and ambulatory BP measurement, and/or
statistical analyses) reviewed at least annually the complete
clinical records of all enrolled subjects to assess CVD
morbidity and mortality. Registered events included: death
from all causes, myocardial infarction, angina pectoris,
coronary revascularization, heart failure, acute arterial oc-
clusion of lower extremities, thrombotic occlusion of the
retinal artery, hemorrhagic stroke, ischemic stroke, and
transient ischemic attack.
Statistical methods. To correct for measurement errors
and outliers, ABPM profiles were edited according to
conventional criteria. Thus, SBP readings 250 or 70
m Hg, DBP 150 or 40 mm Hg, and pulse pressure
difference between SBP and DBP) 150 or 20 mm Hg
were automatically discarded. The sleep-time relative BP
decline (an index of BP dipping), defined as the percentage
decrease in mean BP during nocturnal sleep relative to the
mean BP during daytime activity, was calculated as: ([awake
BP mean  asleep BP mean]/awake BP mean) 100, with
all the data sampled by 48-h ABPM. For comparative
purposes, a subject was defined as dipper if the sleep-timerelative SBP decline was10% and as nondipper otherwise.
The morning BP surge was calculated as the difference
between the average BP during the first 2 h after wake-up
time and the hourly average centered on the lowest noctur-
nal sleep-time BP reading (1). The ambulatory arterial
stiffness index was calculated as 1 minus the regression slope
of DBP on SBP from ABPM (15).
The CVD risk was evaluated based on the: 1) baseline
ABPM evaluation from every participant; and 2) changes in
any tested parameter/participant during follow-up. The
primary outcomes study endpoint was total CVD morbidity
and mortality, which included all the events listed in the
preceding text. We also used, as an additional primary
endpoint, major CVD events (i.e., a composite of CVD
deaths, myocardial infarction, and stroke). Demographic
and clinical characteristics were compared among groups of
subjects experiencing or not experiencing an event by t test
(continuous variables) or nonparametric chi-square test
(proportions). The Cox proportional hazards model, with
adjustment for significant confounding variables, was used
to estimate hazard ratios (HRs) with 95% confidence
intervals (CIs) for events associated with each tested poten-
tial prognostic BP parameter at baseline; these HRs were
standardized by calculating them for 1-SD increments for
each BP parameter. By contrast, the prognostic value of BP
reduction during follow-up was evaluated by entering the
change in the tested ABPM parameter as a time-dependent
covariate in the Cox regression analysis. For survival anal-
ysis, follow-up was established as either the time to the first
documented event or the time to the last evaluation in
event-free subjects. Statistical analyses were performed with
SPSS software (version 13.0 for Macintosh, SPSS, Inc.,
Chicago, Illinois) and KaleidaGraph (version 3.6.4, Synergy
Software, Reading, Pennsylvania).
Results
Demographic characteristics and laboratory variables in
event and nonevent subjects. During the median follow-up
period of 5.6 years (range 0.5 to 8.6 years), we documented 331
first events (58 deaths, 45 myocardial infarctions, 51 angina
pectoris, 35 coronary revascularizations, 44 cerebrovascular
events, 46 heart failures, 21 cases of aortoiliac occlusive disease,
and 31 thrombotic occlusions of the retinal artery).
Event-subjects were: predominantly men; of older age; and
who at baseline were likely to have type 2 diabetes, obstruc-
tive sleep apnea, metabolic syndrome, and/or abdominal
obesity (Table 1). In addition, at baseline they had higher
clinic BP (including pulse pressure, even after correcting for
age), glucose, creatinine, uric acid, triglycerides, plasma
fibrinogen, and erythrocyte sedimentation rate but lower
estimated glomerular filtration rate (Table 1). All differences
between groups reported in Table 1 with a p value 0.002
stand as significant after correcting for multiple testing.
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risk. At baseline, the 48-h mean of SBP but not of DBP
as significantly higher among event-subjects (Table 1).
he largest difference between groups was in asleep SBP
ean. The sleep-time relative BP decline was significantly
Baseline Characteristics of Subjects InvestigateTable 1 Baseline Characteristics of Subject
Variable* No
Demographic characteristics
Patients 3
Male 4
Diabetes 1
Obstructive sleep apnea
Metabolic syndrome 5
Cigarette smoking 1
Obesity 4
Anthropometric variables and office BP
Age, yrs 51
Height, cm 162
Weight, kg 78
BMI, kg/m2 29
Waist, cm 95
Clinic SBP, mm Hg† 149
Clinic DBP, mm Hg† 85
Clinic PP, mm Hg† 63
Clinic HR, beats/min† 74
Clinical laboratory test values
Glucose, mg/dl 106
Creatinine, mg/dl 0.9
Uric acid, mg/dl 5
Total cholesterol, mg/dl 210
Triglycerides, mg/dl 115
HDL cholesterol, mg/dl 48
LDL cholesterol, mg/dl 138
Fibrinogen, mg/dl 319
Erythrocyte sedimentation rate, mm 13
Glomerular filtration rate, ml/min/1.73 m2‡ 80
Ambulatory BP
Awake SBP mean, mm Hg 130
Asleep SBP mean, mm Hg 117
48-h SBP mean, mm Hg 126
Sleep-time relative SBP decline, % 10
Awake DBP mean, mm Hg 81
Asleep DBP mean, mm Hg 68
48-h DBP mean, mm Hg 77
Sleep-time relative DBP decline, % 15
Awake PP mean, mm Hg 49
Asleep PP mean, mm Hg 48
48-h PP mean, mm Hg 49
Sleep-time relative PP decline, % 0
Nondipper 4
Values are shown as n, %, or mean SD. *Metabolic syndrome: Nation
(16). Obesity: body mass index (BMI) 30 kg/m2. The sleep-time rel
percentage decline in mean BP during nocturnal sleep relative to the m
BP mean]/awake BP mean) 100. Nondipper: patients with sleep-tim
ambulatory blood pressure monitoring (ABPM) for 48 consecutive hou
obtained for each subject at the clinic before starting 48-h ABPM. ‡
Epidemiology Collaboration equation (17).
DBP  diastolic blood pressure; HDL  high-density lipoprotein; HRower (p  0.001), and the prevalence of nondipping wassignificantly higher (73% vs. 46%) among event-subjects
(p  0.001) (Table 1).
Table 2 shows the HR of CVD events estimated by the
Cox proportional hazards model, calculated on the basis of
the first ABPM profile from each subject. Adjustments were
estigated
t Event p Value Between Groups
331
70.0% 0.001
32.3% 0.001
16.3% 0.001
70.7% 0.001
12.1% 0.177
48.3% 0.019
4.2 63.5 11.7 0.001
0.0 160.9 9.2 0.002
.6 78.6 15.8 0.904
.1 30.3 5.1 0.033
2.5 99.3 13.3 0.001
.9 161.3 25.2 0.001
.1 86.8 13.6 0.152
.3 74.5 18.4 0.001
.2 72.7 13.1 0.002
.9 120.4 44.9 0.001
23 1.07 0.32 0.001
6 6.3 1.9 0.001
.1 211.2 43.2 0.635
.1 126.5 65.6 0.015
.6 46.3 14.2 0.046
.4 141.2 34.8 0.169
.7 348.0 86.6 0.001
.4 20.0 20.8 0.001
7.9 71.7 18.5 0.001
.0 139.2 18.2 0.001
.9 133.5 22.3 0.001
.7 137.2 18.5 0.001
9 4.2 10.0 0.001
.6 79.5 12.5 0.012
.2 71.7 11.8 0.001
.2 76.9 11.7 0.680
7 9.4 10.4 0.001
.1 59.7 14.7 0.001
.3 61.8 17.6 0.001
.0 60.3 15.3 0.001
1 3.5 12.8 0.001
72.5% 0.001
esterol Education Program Adult Treatment Panel III revised definition
lood pressure (BP) decline, an index of BP dipping, is defined as the
during daytime activity and calculated as: ([awake BPmean asleep
ive systolic blood pressure (SBP) decline10%, with data sampled by
lues correspond to the average of 6 conventional BP measurements
rular filtration rate was estimated with the Chronic Kidney Disease
rt rate; LDL  low-density lipoprotein; PP  pulse pressure.ds Inv
Even
,013
9.6%
6.6%
8.6%
0.4%
4.8%
1.6%
.4 1
.6 1
.5 15
.7 5
.4 1
.7 18
.8 11
.9 13
.8 12
.0 31
5 0.
.7 1.
.0 40
.1 79
.2 15
.3 34
.7 78
.7 11
.1 1
.5 14
.3 14
.4 13
.1 6.
.1 10
.5 10
.1 10
.3 7.
.4 10
.8 10
.3 10
.8 9.
6.0%
al Chol
ative b
ean BP
e relat
rs. †Va
Glomeapplied for sex, age, and diabetes (left column), because
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demographic and laboratory variables shown in Table 1—that
were consistently significant in all tested models. Results
documented increased CVD risk associated with older age
(HR: 1.07, 95% CI: 1.06 to 1.08, p  0.001, for each
additional year of age), male sex (HR: 2.44, 95% CI: 1.93 to
3.08, p  0.001, compared with women), and presence of
diabetes (HR: 1.53, 95% CI: 1.21 to 1.94, p  0.001,
compared with no diabetes). Results remained mainly un-
changed when the Cox proportional hazards models were
further adjusted by baseline clinic BP (Table 2, right
column); clinic BP was not a significant predictor of
outcome in the models including asleep or 48-h BP mean.
Moreover, a greater morning BP surge, calculated as defined
(1), was significantly associated with lower CVD risk (Table 2).
Finally, when asleep and awake SBP mean were used jointly
in the same Cox regression model, only the former was a
HRs of Total and Major CVD Events Associated With Baseline CliniTable 2 HRs of Total and Major CVD Events Associated With B
Total CVD Events
Parameters Adjusted HR Further Adjustm
SBP
Clinic 1.35 (1.22–1.49)* —
Awake mean 1.35 (1.23–1.49)* 1.23 (1.0
Asleep mean 1.52 (1.40–1.66)* 1.48 (1.3
48-h mean 1.43 (1.31–1.57)* 1.35 (1.2
Sleep-time relative decline 0.72 (0.66–0.79)* 0.74 (0.6
SD, awake 1.29 (1.18–1.42)* 1.21 (1.0
SD, asleep 1.22 (1.11–1.34)* 1.12 (1.0
SD, 48 h 1.24 (1.13–1.36)* 1.14 (1.0
Morning surge 0.79 (0.72–0.86)* 0.79 (0.7
DBP
Clinic 1.12 (1.01–1.25)‡ —
Awake mean 1.07 (0.95–1.20) 0.98 (0.8
Asleep mean 1.30 (1.17–1.44)* 1.31 (1.1
48-h mean 1.15 (1.02–1.29)‡ 1.10 (0.9
Sleep-time relative decline 0.73 (0.66–0.80)* 0.72 (0.6
SD, awake 1.17 (1.06–1.30)† 1.15 (1.0
SD, asleep 1.08 (0.98–1.19) 1.06 (0.9
SD, 48 h 1.05 (0.95–1.17) 1.02 (0.9
Morning surge 0.75 (0.68–0.83)* 0.74 (0.6
PP
Clinic 1.35 (1.23–1.48)* —
Awake mean 1.38 (1.26–1.51)* 1.26 (1.1
Asleep mean 1.44 (1.34–1.56)* 1.43 (1.2
48-h mean 1.42 (1.31–1.55)* 1.36 (1.1
Sleep-time relative decline 0.79 (0.72–0.86)* 0.80 (0.7
SD, awake 1.31 (1.19–1.45)* 1.18 (1.0
SD, asleep 1.26 (1.15–1.38)* 1.16 (1.0
SD, 48 h 1.37 (1.26–1.50)* 1.26 (1.1
Morning surge 0.89 (0.81–0.98)‡ 0.89 (0.8
AASI 1.38 (1.22–1.57)* 1.31 (1.1
Hazard ratio (HR) (95% confidence interval [CI]) was standardized by calculating for 1-SD incremen
diabetes). The sleep-time relative BP decline, an index of BP dipping, is defined as the percentage
([awake BPmean asleep BPmean]/awake BPmean) 100. Themorning BP surge was calculat
centered on the lowest BP reading recorded during nocturnal sleep. The ambulatory arterial stiff
0.001; †p  0.01; ‡p  0.05.
CVD  cardiovascular disease; other abbreviations as in Table 1.significant predictor of outcome. Most important, the asleepBP mean was also a most significant predictor of major
CVD events (HR: 1.84, 95% CI: 1.60 to 2.11 for 1-SD
elevation in asleep SBP mean, p  0.001) (Table 2, right
columns).
Changes in clinic and ambulatory BP during follow-up
as predictors of CVD risk. Table 3 (left column) shows
the results from time-dependent Cox regression analysis
(adjusted by age, sex, diabetes, baseline BP, and number of
hypertension medications used for treatment) for total CVD
events. The progressive decrease in awake, asleep, and 48-h
BP mean was associated with significantly increased sur-
vival. Changes in SD, morning BP surge, and ambulatory
arterial stiffness index during follow-up were mainly not
significantly associated with reduced/increased risk. The
decrease in asleep BP mean during follow-up was also a
significant predictor of survival from major events (HR:
0.81, 95% CI: 0.73 to 0.91 for SBP; HR: 0.68, 95% CI: 0.56
Ambulatory BPne Clinic and Ambulatory BP
Major CVD Events
Clinic BP Adjusted HR Further Adjustment by Clinic BP
1.68 (1.41–2.00)* —
8)† 1.61 (1.39–1.88)* 1.36 (1.12–1.65)†
4)* 1.84 (1.60–2.11)* 1.69 (1.43–2.01)*
1)* 1.72 (1.49–1.99)* 1.52 (1.26–1.84)*
1)* 0.65 (0.56–0.75)* 0.65 (0.56–0.77)*
3)* 1.51 (1.30–1.75)* 1.36 (1.15–1.61)*
5)‡ 1.43 (1.22–1.67)* 1.26 (1.06–1.49)†
7)‡ 1.41 (1.22–1.64)* 1.27 (1.06–1.51)†
7)* 0.75 (0.63–0.89)† 0.76 (0.65–0.89)†
1.35 (1.12–1.64)† —
4) 1.37 (1.11–1.69)† 1.19 (0.91–1.56)
8)* 1.65 (1.38–1.98)* 1.61 (1.31–1.99)*
8) 1.50 (1.23–1.84)* 1.40 (1.08–1.81)†
9)* 0.65 (0.54–0.77)* 0.63 (0.53–0.76)*
8)† 1.44 (1.23–1.69)* 1.37 (1.16–1.63)*
7) 1.19 (1.01–1.41)‡ 1.14 (0.96–1.35)
4) 1.20 (0.99–1.44) 1.11 (0.92–1.35)
2)* 0.78 (0.64–0.04)† 0.76 (0.63–0.91)†
1.61 (1.37–1.89)* —
4)* 1.50 (1.29–1.73)* 1.21 (0.98–1.50)
1)* 1.67 (1.47–1.91)* 1.56 (1.28–1.90)*
4)* 1.58 (1.37–1.82)* 1.36 (1.10–1.68)†
8)* 0.70 (0.61–0.81)* 0.69 (0.60–0.80)*
2)† 1.50 (1.27–1.77)* 1.28 (1.05–1.56)‡
8)† 1.46 (1.26–1.69)* 1.29 (1.10–1.52)†
0)* 1.65 (1.42–1.91)* 1.47 (1.23–1.76)*
7)† 0.82 (0.70–0.97)‡ 0.81 (0.69–0.94)†
9)* 1.45 (1.20–1.87)* 1.36 (1.07–1.71)‡
stments were applied for the only consistently significant influential characteristics (sex, age, and
e in BP during nocturnal sleep relative to the mean BP during daytime activity and calculated as:
e difference between the average BP during the first 2 h after wake-up time and the hourly average
dex (AASI) was calculated as 1 minus the regression slope of DBP on SBP from ABPM. *p c andaseli
ent by
9–1.3
3–1.6
0–1.5
8–0.8
9–1.3
2–1.2
3–1.2
3–0.8
4–1.1
6–1.4
5–1.2
5–0.7
4–1.2
6–1.1
1–1.1
7–0.8
1–1.4
7–1.6
9–1.5
3–0.8
5–1.3
5–1.2
3–1.4
1–0.9
6–1.4
ts. Adju
declin
ed as th
ness into 0.82 for DBP; p 0.001) (Table 3, right column). When
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Changes in Ambulatory BP and Cardiovascular Risk September 6, 2011:1165–73the changes in asleep and awake BP mean were used jointly
in the same Cox regression model, only the decrease in
asleep BP mean was significant associated with increased
survival.
When subjects were categorized according to their base-
line assessment with the ABPM threshold values previously
outlined, the reduced HR associated with each 5-mm Hg
decrease in asleep SBP mean during follow-up was signif-
icant for both subjects with either normal (HR: 0.81, 95%
CI: 0.68 to 0.95, p 0.005) or elevated BP (HR: 0.84, 95%
CI: 0.79 to 0.89, p  0.001). For this latter group, the
increased survival associated with reducing asleep SBP mean
was statistically significant independently of treatment time
(HR: 0.88, 95% CI: 0.82 to 0.95, p  0.001, for patients
Adjusted HR of Total and Major CVD Events AssWith Reducti n in C inic and Ambulatory BP DuTable 3 Adjus ed HR of T tal and Major CVWith Reduction in Clinic and Ambul
Parameters Total Events
SBP
Clinic BP 0.93 (0.89–0.97)* 0
Awake mean 0.86 (0.81–0.91)† 0
Asleep mean 0.83 (0.78–0.87)† 0
48-h mean 0.84 (0.79–0.90)† 0
Sleep-time relative decline 0.75 (0.67–0.84)† 0
SD, awake 0.98 (0.94–1.03) 1
SD, asleep 0.96 (0.92–1.00)‡ 0
SD, 48 h 0.99 (0.94–1.04) 1
Morning surge 0.99 (0.98–1.01) 1
DBP
Clinic BP 0.85 (0.78–0.92)† 0
Awake mean 0.79 (0.72–0.87)† 0
Asleep mean 0.71 (0.65–0.77)† 0
48-h mean 0.73 (0.67–0.80)† 0
Sleep-time relative decline 0.76 (0.69–0.84)† 0
SD, awake 0.97 (0.91–1.04) 0
SD, asleep 0.96 (0.91–1.02) 0
SD, 48 h 1.06 (0.98–1.14) 1
Morning surge 1.00 (0.97–1.02) 1
PP
Clinic BP 0.94 (0.88–1.00)‡ 0
Awake mean 0.86 (0.77–0.97)‡ 0
Asleep mean 0.84 (0.75–0.94)* 0
48-h mean 0.85 (0.76–0.96)* 0
Sleep-time relative decline 0.92 (0.84–0.99)‡ 0
SD, awake 0.96 (0.89–1.04) 0
SD, asleep 0.93 (0.87–0.99)‡ 0
SD, 48 h 0.93 (0.86–1.01) 0
Morning surge 0.99 (0.97–1.01) 1
AASI 0.87 (0.76–1.00) 0
Left columns: Hazard ratio (95% CI) for each 5-mm Hg decrease in BP,
surge, and 0.1 decrease in AASI during follow-up. Right columns provi
during follow-up. Adjustments were applied for the only significant
hypertension medications used for treatment). Change in BP was e
sleep-time relative BP decline, an index of BP dipping, is defined as t
during daytime activity and calculated as: ([awake BP mean asleep
the difference between the average BP during the first 2 h after wake
during nocturnal sleep. The AASI was calculated as 1 minus the regre
Abbreviations as in Tables 1 and 2.reated with all medications on awakening; HR: 0.76, 95% sI: 0.67 to 0.86, p  0.001, for those treated with 1
edication at bedtime).
Figure 1 shows, for the studied population divided in
uintiles, the relationship between the decrease in asleep SBP
ean from baseline and CVD risk. Adjusted HR was signif-
cantly higher (p  0.001) in the last 3 quintiles, compared
ith the first 2 classes. There was a progressive reduction from
7% to 36% in the percentage of hypertensive subjects treated
t bedtime across the quintiles, somehow indicating the asso-
iation between bedtime-treatment, increased asleep BP re-
uction, and decreased CVD risk. Figure 2 shows a J-shaped
elationship between changes in clinic SBP during follow-up
nd CVD risk; the adjusted HR was significantly higher (p 
.008) in the first than in the second quintile, and then it
tedollow-Upnts Associated
BP During Follow-Up
r Events Total Events Major Events
85–1.02) 0.73 (0.63–0.86)† 0.78 (0.57–1.06)
75–0.95)* 0.66 (0.58–0.78)† 0.65 (0.49–0.88)*
73–0.91)† 0.61 (0.53–0.71)† 0.60 (0.45–0.80)†
74–0.92)* 0.63 (0.54–0.73)† 0.62 (0.46–0.82)*
57–0.88)† 0.67 (0.57–0.79)† 0.62 (0.46–0.83)†
93–1.09) 0.94 (0.80–1.09) 1.03 (0.78–1.35)
89–1.05) 0.84 (0.72–0.98)‡ 0.87 (0.64–1.18)
95–1.13) 0.97 (0.82–1.14) 1.12 (0.82–1.52)
98–1.03) 0.98 (0.83–1.17) 1.13 (0.80–1.60)
73–1.02) 0.69 (0.58–0.82)† 0.73 (0.52–1.03)
63–0.93)* 0.65 (0.54–0.77)† 0.64 (0.46–0.89)*
56–0.82)† 0.54 (0.46–0.63)† 0.51 (0.37–0.72)†
57–0.87)* 0.58 (0.49–0.68)† 0.58 (0.42–0.80)*
63–0.93)* 0.64 (0.54–0.75)† 0.65 (0.48–0.89)*
84–1.08) 0.92 (0.78–1.09) 0.89 (0.66–1.19)
87–1.09) 0.90 (0.75–1.07) 0.93 (0.67–1.30)
92–1.21) 1.16 (0.97–1.39) 1.14 (0.82–1.60)
97–1.05) 1.17 (0.98–1.41) 1.18 (0.83–1.67)
83–1.09) 0.85 (0.72–0.99)‡ 0.89 (0.66–1.21)
71–1.10) 0.83 (0.72–0.96)‡ 0.84 (0.64–1.11)
65–0.98)‡ 0.80 (0.69–0.92)* 0.75 (0.57–0.98)‡
67–1.05) 0.83 (0.72–0.95)* 0.81 (0.62–1.06)
70–0.98)‡ 0.84 (0.71–0.99)‡ 0.69 (0.50–0.96)‡
84–1.12) 0.92 (0.78–1.08) 0.94 (0.70–1.27)
86–1.11) 0.84 (0.72–0.98)‡ 0.94 (0.70–1.26)
83–1.13) 0.87 (0.75–1.02) 0.94 (0.70–1.26)
96–1.04) 0.91 (0.76–1.08) 1.00 (0.71–1.41)
72–1.22) 0.84 (0.69–1.00) 0.91 (0.64–1.31)
rease in sleep-time relative BP decline, 1-mm Hg decrease in morning
tandardized by calculating for 1-SD change in each ABPM parameter
ial characteristics (sex, age, diabetes, baseline BP, and number of
as a time-dependent covariate in the Cox regression models. The
entage decline in BP during nocturnal sleep relative to the mean BP
n]/awake BP mean) 100. The morning BP surge was calculated as
and the hourly average centered on the lowest BP reading recorded
lope of DBP on SBP from ABPM. *p  0.01; †p  0.001; ‡p  0.05.ociaring FD Eve
atory
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treated at bedtime was lower (45%) in the first as compared
with the second quintile (56%).
Discussion
The MAPEC study is the first to prospectively assess the
prognostic value of changes in ABPM parameters during a
follow-up time of sufficient duration by systematic periodic
evaluation, with highly reproducible 48-h ABPM and wrist
Figure 1 HR as a Function of the Change in Asleep SBP Mean
Hazard ratio (HR) was adjusted by age, sex, diabetes, baseline blood pressure (BP
Studied population was divided into 5 classes of equal size (quintiles). Negative c
Figure 2 HR as a Function of the Change in Clinic SBP During
The HR was adjusted by age, sex, diabetes, baseline BP, and number of hyperten
was divided into 5 classes of equal size (quintiles). Negative change indicates a Bactigraphy, in a relatively large cohort of subjects with
baseline BP ranging from normotension to hypertension.
The results corroborate a higher prognostic value of ABPM
over clinic BP measurements as documented in previous
studies (3,5). Analyses based on a single ABPM profile from
each subject obtained at baseline (as customary in all
previous studies on this topic) indicate that the asleep SBP
mean was a most significant predictor of CVD events
(Table 2). Moreover, when asleep SBP mean was adjusted
g Follow-Up
number of hypertension medications used for treatment.
indicates a BP reduction during follow-up. SBP  systolic blood pressure.
w-Up
edications used for treatment. Studied population
ction during follow-up. Abbreviations as in Figure 1.Durin
), and
hangeFollo
sion m
P redu
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Changes in Ambulatory BP and Cardiovascular Risk September 6, 2011:1165–73by awake SBP mean, only the former was a significant
predictor of outcome.
Most important from the therapeutic point of view, the
evaluation of changes in ABPM during follow-up docu-
mented that the progressive decrease in asleep BP mean was
significantly associated with event-free survival. The rela-
tionship between decreasing asleep BP and reduced CVD
risk was significant for subjects with either normal or
elevated ambulatory BP analyzed separately, suggesting
risk-reduction benefits even below the current diagnostic
threshold of 120 mm Hg for asleep SBP mean. All together,
these results not only corroborate that the asleep BP mean
is the most significant prognostic marker of CVD morbidity
and mortality, as previously suggested (5–10), but also
document for the first time that decreasing asleep BP mean
significantly reduces CVD risk.
The findings summarized in Table 3 from this prospec-
tive study suggest the asleep BP mean should be considered
a novel therapeutic target for reduction of CVD risk. Along
these lines, a number of previous prospective trials reviewed
elsewhere (18) have detected meaningful morning/evening
treatment-time differences in BP-lowering efficacy, duration
of action, safety profile, and/or effects on the circadian BP
pattern of different classes of hypertension medications. For
instance, a once-daily evening, in comparison with morning,
ingestion schedule of angiotensin receptor blockers and
angiotensin-converting enzyme inhibitors results in greater
therapeutic effect on asleep BP independently of the termi-
nal half-life of each individual medication (18). Thus, the
impact of hypertension treatment-time on sleep-time BP
regulation might be clinically relevant. The previously re-
ported results of the randomized part of the MAPEC study
indicate that treatment with 1 medication at bedtime was
significantly associated with greater asleep BP reduction and
significantly lower CVD risk than treatment with all hyper-
tension medications upon awakening (14).
Therapeutic intervention in hypertension consists of ad-
equate control of BP, the goal being to reduce/avert CVD
morbidity and mortality. Some studies found that too high
a reduction in clinic BP might be associated with increased
CVD risk, whereas moderate reduction in clinic BP would
decrease it. Thus, it has been suggested that CVD outcomes
have a J-shaped relationship to BP, decreasing as BP was
lowered and rising again as BP decreased further (19–21).
We also found a J-shaped association in the relation
between CVD risk and changes in clinic BP (Fig. 2) but not
with changes in asleep BP mean (Fig. 1). The CVD risk
decreased with progressive reduction in asleep BP mean.
Moreover, the amount of the asleep BP reduction during
follow-up was significantly correlated with increased num-
ber of patients treated at bedtime. It has been previously
shown that increasing number of hypertension medications
administered in the morning might lead to more intensive
clinic BP reduction but also to an increased prevalence of
nondipping as a consequence of the greater reduction in
awake than asleep BP (22). We thus conclude that theactual controversy on the possible J-shaped relation with
CVD risk, described so far only for clinic BP determined in
patients presumably treated in the morning (19–21), might
not apply (when avoiding nocturnal hypotension) to asleep
BP, a more significant predictor of CVD morbidity and
mortality.
Study limitations. First, compared with other larger mul-
ticenter clinical trials on hypertensive patients entailing only
clinic BP during follow-up, the sample size of the single-
center MAPEC study might seem a limitation. However,
the number of subjects participating in our study was
considerably greater than that of most other published trials
on the prognostic value of ABPM (3,4). Second, like most
other studies in this field, inclusion criteria restricted the
study to subjects with suspected or previously diagnosed
hypertension. Nonetheless, the design of the MAPEC
study also incorporates several strengths. Although all pre-
vious trials on the prognostic value of ABPM had relied on
a single baseline profile from each subject, the MAPEC
study is the first to provide results that are based on
systematic periodic multiple evaluations by ABPM
throughout the median 5.6 years of follow-up. This so-far
unique approach allowed determination of the influence on
CVD risk of specific changes during follow-up in relevant
ABPM parameters. Further strengths of the MAPEC study
are the use of: 1) 48-h instead of the most common 24-h
ABPM sampling, to increase the reproducibility of the BP
findings (23); and 2) wrist actigraphy to precisely and
individually determine the beginning and end of the activity
and sleep spans for each subject to enable the accurate
calculation of the awake and asleep BP means.
Conclusions
Current international guidelines have already recognized the
prognostic value of ABPM and suggest limited clinical
situations in which the technique is recommended. These
situations include: suspected white-coat hypertension, resis-
tant hypertension, hypotensive symptoms after treatment,
episodic hypertension, and autonomic dysfunction (13).
Our findings further support ABPM for proper CVD risk
assessment, taking into account the prognostic value of
asleep BP, a novel therapeutic target requiring patient
evaluation by ABPM. Moreover, the decreased CVD risk
associated with progressively reducing the asleep BP mean
suggests the need to use ABPM for the routine evaluation of
treatment efficacy and proper definition of BP control.
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APPENDIX
For the extended version of the Methods,
please see the online version of this paper.
